Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by cardiometabolic risk factors (CMRFs). Treatment of CMRFs is the cornerstone of MASLD management, yet other than weight loss, the association between changes in CMRFs and changes in liver-related measures is not defined. This study aimed to characterize these longitudinal associations using non-invasive measurements of hepatic fibrosis and steatosis.
Journal of Hepatology published a clinical update in Research Highlights on 11 Feb 2026.
The item focuses on Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD.
Review the original article for the full source wording and details.